請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27851
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 翁啟惠(Chi-Huey Wong) | |
dc.contributor.author | Ching-Yao Su | en |
dc.contributor.author | 蘇敬堯 | zh_TW |
dc.date.accessioned | 2021-06-12T18:24:03Z | - |
dc.date.available | 2012-08-22 | |
dc.date.copyright | 2011-08-22 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-21 | |
dc.identifier.citation | 1. Wagner, R., Matrosovich, M. & Klenk, H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12, 159-166 (2002).
2. Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual review of biochemistry 69, 531-569 (2000). 3. Steinhauer, D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258, 1-20 (1999). 4. Lakadamyali, M., Rust, M.J., Babcock, H.P. & Zhuang, X. Visualizing infection of individual influenza viruses. Proc Natl Acad Sci U S A 100, 9280-9285 (2003). 5. Cros, J.F. & Palese, P. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Res 95, 3-12 (2003). 6. Nayak, D.P., Hui, E.K. & Barman, S. Assembly and budding of influenza virus. Virus Res 106, 147-165 (2004). 7. Meisner, J., et al. Infectivity studies of influenza virus hemagglutinin receptor binding site mutants in mice. J Virol 82, 5079-5083 (2008). 8. Nicholls, J.M., et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 13, 147-149 (2007). 9. Stevens, J., et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. Journal of molecular biology 355, 1143-1155 (2006). 10. Margo, K.L. & Shaughnessy, A.F. Antiviral drugs in healthy children. Am Fam Physician 57, 1073-1077 (1998). 11. Deyde, V.M., et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196, 249-257 (2007). 12. Rahman, M., et al. Adamantane-resistant influenza infection during the 2004-05 season. Emerg Infect Dis 14, 173-176 (2008). 13. Dunn, C.J. & Goa, K.L. Zanamivir: a review of its use in influenza. Drugs 58, 761-784 (1999). 14. von Itzstein, M., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418-423 (1993). 15. Oxford, J.S., Mann, A. & Lambkin, R. A designer drug against influenza: the NA inhibitor oseltamivir (Tamiflu). Expert Rev Anti Infect Ther 1, 337-342 (2003). 16. Oxford, J., Balasingam, S. & Lambkin, R. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community. J Antimicrob Chemother 53, 133-136 (2004). 17. Shie, J.J., et al. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 129, 11892-11893 (2007). 18. Macdonald, S.J., et al. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 48, 2964-2971 (2005). 19. Macdonald, S.J., et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother 48, 4542-4549 (2004). 20. Wen, W.H., et al. Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus. J Med Chem 52, 4903-4910 (2009). 21. McKimm-Breschkin, J.L., et al. Tethered neuraminidase inhibitors that bind an influenza virus: a first step towards a diagnostic method for influenza. Angew Chem Int Ed Engl 42, 3118-3121 (2003). 22. Drake, J.W. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90, 4171-4175 (1993). 23. Hilleman, M.R. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20, 3068-3087 (2002). 24. Palese, P. Influenza: old and new threats. Nat Med 10, S82-87 (2004). 25. Tambunan, U.S. & Ramdhan. Identification of sequence mutations affecting hemagglutinin specificity to sialic acid receptor in influenza A virus subtypes. Bioinformation 5, 244-249 (2010). 26. Smith, G.J., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459, 1122-1125 (2009). 27. de Jong, J.C., Claas, E.C., Osterhaus, A.D., Webster, R.G. & Lim, W.L. A pandemic warning? Nature 389, 554 (1997). 28. Nicholls, H. Pandemic influenza: the inside story. PLoS Biol 4, e50 (2006). 29. Yen, H.L., et al. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 81, 12418-12426 (2007). 30. Hatakeyama, S., et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Jama 297, 1435-1442 (2007). 31. Moscona, A. Oseltamivir resistance--disabling our influenza defenses. N Engl J Med 353, 2633-2636 (2005). 32. von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6, 967-974 (2007). 33. Collins, P.J., et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453, 1258-1261 (2008). 34. Le, Q.M., et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108 (2005). 35. Tashiro, M., et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther 14, 751-761 (2009). 36. Baranovich, T., et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J Clin Virol 47, 23-28 (2010). 37. Hurt, A.C., et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83, 90-93 (2009). 38. Hamelin, M.E., et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 6, e1001015 (2010). 39. Das, K., Aramini, J.M., Ma, L.C., Krug, R.M. & Arnold, E. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 17, 530-538 (2010). 40. Gong, J., et al. Potential targets and their relevant inhibitors in anti-influenza fields. Curr Med Chem 16, 3716-3739 (2009). 41. Alymova, I.V., Taylor, G. & Portner, A. Neuraminidase inhibitors as antiviral agents. Curr Drug Targets Infect Disord 5, 401-409 (2005). 42. De Clercq, E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5, 1015-1025 (2006). 43. Onodera, S. A microplate assay for sialidase activity using plant lectin binding to N-acetyllactosamine. Biol Pharm Bull 17, 29-33 (1994). 44. Franca de Barros, J., Jr., et al. Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity. Intervirology 46, 199-206 (2003). 45. Guo, L., et al. Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res 82, 29-33 (2009). 46. Bolotin, S., et al. Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates. J Virol Methods 158, 190-194 (2009). 47. Monto, A.S. The risk of seasonal and pandemic influenza: prospects for control. Clin Infect Dis 48 Suppl 1, S20-25 (2009). 48. Hampson, A.W. Avian influenza: a pandemic waiting in the wings? Emerg Med Australas 18, 420-429 (2006). 49. Shie, J.J., et al. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 129, 11892-11893 (2007). 50. Palese, P., Tobita, K., Ueda, M. & Compans, R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61, 397-410 (1974). 51. Fedorko, D.P., Nelson, N.A., McAuliffe, J.M. & Subbarao, K. Performance of rapid tests for detection of avian influenza A virus types H5N1 and H9N2. Journal of clinical microbiology 44, 1596-1597 (2006). 52. Temperton, N.J., et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza and other respiratory viruses 1, 105-112 (2007). 53. Cabezas, J.A., Reglero, A. & Hannoun, C. A fluorometric procedure for measuring the neuraminidase activity: its application to the determination of this activity in influenza and parainfluenza viruses. Analytical biochemistry 131, 121-126 (1983). 54. Lutz, A., Dyall, J., Olivo, P.D. & Pekosz, A. Virus-inducible reporter genes as a tool for detecting and quantifying influenza A virus replication. J Virol Methods 126, 13-20 (2005). 55. Neumann, G., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96, 9345-9350 (1999). 56. Wen, W.H., et al. Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus. J Med Chem 52, 4903-4910 (2009). 57. Liu, W., Oseroff, A.R. & Baumann, H. Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokine responsiveness in epithelial cells. Cancer Res 64, 6579-6587 (2004). 58. Kao, R.Y., et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28, 600-605 (2010). 59. Kale, R.R., et al. Detection of intact influenza viruses using biotinylated biantennary S-sialosides. J Am Chem Soc 130, 8169-8171 (2008). 60. Liao, H.Y., et al. Differential receptor binding affinities of influenza hemagglutinins on glycan arrays. J Am Chem Soc 132, 14849-14856 (2010). 61. Wang, C.C., et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A 106, 18137-18142 (2009). 62. Stevens, J., Blixt, O., Paulson, J.C. & Wilson, I.A. Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol 4, 857-864 (2006). 63. Galarza, J.M., Latham, T. & Cupo, A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18, 244-251 (2005). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27851 | - |
dc.description.abstract | 高病原性H5N1禽流感和H1N1豬流感病毒的出現發出了一個很嚴重的警告,主要是因為既有的流感疫苗對於這些病毒都是沒有效的。目前神經氨酸苷酶抑制劑仍是我們最有效的治療方法。但不幸地,自從2009年季節性流感突然地幾乎全部都對克流感產生了抗藥性。在這些被高病原性H5N1禽流感或H1N1豬流感病毒感染的病人中也發現了對克流感具有抗藥性的突變株。然而一般人最擔心的,豬流感病毒在未來是否也會全面都變成具有抗藥性的突變株。因此,其它不同於神經氨酸苷酶抑制劑之預防性的和治療性的化合物都是需要的。另外,研發抗流感葯物之生物分析,現有葯物的改良與修飾,利用高通量篩選來找出新抗流感的抑制劑,研發對克流感敏感度和流感病毒種類的診斷工具和針對流感進行新疫苗的研發都是非常重要的。朝著這些目標,我們研發出一個以細胞為基礎的神經氨酸苷酶分析,其最主要是測量釋放出的紅血球凝集素偽病毒顆粒來進行分析。紅血球凝集素偽病毒顆粒的釋放可以使我們得知神經氨酸苷酶抑制劑的效力。同時針對一個修飾的神經氨酸苷酶抑制劑(扎納米爾叶啉包含了四個扎納米爾和一個叶啉)進行機制的探討,扎納米爾叶啉在流感病毒的感染實驗或是在紅血球凝集素偽病毒顆粒的釋放分析中都得到比單一個扎納米爾有更好的抗病毒效果。我們利用高通量篩選系統找出新的抗流感化合物並證實其作用模式是針對流感病毒核醣核酸聚合酶為標的進行抑制作用。我們也研發了一個新的分析方法其最主要是利用競爭的結合來評估病毒之抗藥性,並且結合醣晶片的應用,建立一個快速又簡單的測試方法去分析流感病毒對克流感的抗藥性和其紅血球凝集素的種類。最後, 我們利用單醣流感紅血球凝集素包覆類病毒顆粒以產生更具有效力的流感疫苗。 | zh_TW |
dc.description.abstract | The appearance of the highly pathogenic H5N1 avian flu and the pandemic H1N1 swine flu cause serious alarms because the existing influenza vaccine is insufficient to prevent the spread of these viruses. The neuraminidase inhibitors are the most effective therapeutic measures we have at this time. Unfortunately, the seasonal flu since 2009 were almost all resistant to oseltamivir. The oseltamivir resistant mutant was also found in patients infected with the highly pathogenic H5N1 avian flu and H1N1 swine flu. The general concern is that whether future pandemic influenza virus will be oseltamivir resistant or not. Therefore, other prophylactics and therapeutic compounds are necessary for preventing influenza infection. The bioassays to study anti-influenza leads, the compound modifications for more efficacious neuraminidase inhibitors, the screenings to identify new anti-influenza inhibitors, the diagnostic tools for oseltamivir resistant viruses and new vaccine development for pandemic influenza are important. Toward these objectives, we developed new cell-base neuraminidase inhibition assay by measuring the releases of HA pseudotype particle (HApp). HApp release assay allows to measure the potencies of the neuraminidase inhibitors under physiological conditions. We studied the mechanism of a potent neuraminidase inhibitor, zanamivir porphyrin, that contains four zanamivirs linked to porphyrin. Zanamivir porphyrin is more efficacious than zanamivir in influenza infectivity and HApp release assays. We also elucidated the mode of action of a new anti-influenza compound identified by HTS. The anti-influenza, compound 3061, targeted influenza NP and affected the activity of RdRP (RNA dependent RNA polymerase). A novel RABC assay (Resistant Assessment by Binding Competition) was developed to determine the oseltamivir susceptibility of influenza neuraminidase. It is also combined with glycan array (influenza HA-binding specificity) to allow a quick and simple test for oseltamivir susceptibility and influenza HA typing. Finally, we also prepared mg HA-VLP (monoglycosylated hemagglutinin virus like particle) that is more effective than fg HA-VLP in preventing influenza infection. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T18:24:03Z (GMT). No. of bitstreams: 1 ntu-100-D95b46008-1.pdf: 3794612 bytes, checksum: a32dc517ff776be0c7fc8a8031be0ef8 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 IV ABSTRACT V CONTENTS VII FIGURE CONTENTS IX TABLE CONTENTS XI ABBREVIATION XII INTRODUCTION 1 MATERIALS AND METHODS 12 COMPOUNDS 12 VIRUSES, CELL LINES, ANTIBODIES, AND REAGENTS 12 THE TCID50 DETERMINATION 14 PLASMID CONSTRUCTIONS 14 HA PSEUDOTYPE PARTICLE (HAPP) PREPARATION 15 DETERMINATION OF HA PSEUDOTYPE PARTICLE ACTIVITY BY TRANSDUCTION 16 HA PSEUDOTYPE PARTICLE (HAPP) RELEASE ASSAY FOR EVALUATION OF NEURAMINIDASE INHIBITORS (NAIS) 16 NEURAMINIDASE ACTIVITY ASSAY AND IC50 DETERMINATION BY AN ENZYMATIC INHIBITION ASSAY 17 INFLUENZA VIRUS INFECTIVITY ASSAY 17 PREPARATION OF OLIGOSACCHARIDES AND SUGAR ARRAY-BINDING ASSAYS 18 ANTI-INFLUENZA INFECTIVITY DETERMINED BY PLAQUE ASSAYS 19 INDIRECT IMMUNOFLUORESCENCE STAINING AND CONFOCAL MICROSCOPY 20 CELL-BASED INFLUENZA RNA BY AN RNA-DEPENDENT POLYMERASE (RDRP) ASSAY 20 PREPARATION OF ISOGENIC RECOMBINANT INFLUENZA VIRUSES 21 PREPARATION OF 293T CELLS STABLY EXPRESSING PARENTAL OR OSELTAMIVIR-RESISTANT MUTANT (H274Y) NA 22 OSELTAMIVIR-SUSCEPTIBILITY ASSAY USING NA-EXPRESSING CELLS 23 RABC ASSAY USING A SUGAR ARRAY FOR SIMULTANEOUS INFLUENZA HA TYPING AND OSELTAMIVIR SUSCEPTIBILITY DETERMINATION 23 RESULTS 25 PART I: ESTABLISHMENT OF THE HAPP RELEASE ASSAY, MIMICKING INFLUENZA RELEASE PROCESS, FOR EVALUATING THE POTENCIES OF NEURAMINIDASE INHIBITORS. 25 1. Establishment of HApp releasing assay to evaluate the potencies of neuraminidase inhibitors. 25 2. Zanamivir porphyrin causes neuraminidase cross linkage and degradation. 30 3. A new anti-influenza, compound 3061, inhibits influenza RdRP activity and causes influenza NP aggregation and degradation 37 PART II. DEVELOPMENT OF A METHOD QUICKLY AND CORRECTLY TO IDENTIFY OSELTAMIVIR SUSCEPTIBILITY AND INFLUENZA HA TYPING 39 1. Development of RABC assay using neuraminidase stable cell line as a model system 39 2. Clinical influenza isolates were used to determine oseltamivir susceptibility by RABC assay 41 3. Development of a new method combining RABC assay and glycan array for identifications of oseltamivir susceptibility and influenza hemagglutinin typing 41 4. Establishing hemagglutinin binding profiles on glycan arrays using HApp and influenza viruses. 44 PART III: TO ESTABLISH MGH1-VLP (MONOGLYCOSYLATED HEMAGGLUTININ VIRAL LIKE PARTICLE) AS VACCINE AGAINST PANDEMIC INFLUENZA 46 1. HA-VLP production from insect cell expression system 47 2. Preparation of mg-HA-VLP preparation and the quantitative of hemagglutinin contents 47 DISCUSSIONS 49 REFERENCES: 94 | |
dc.language.iso | en | |
dc.title | 病毒檢測之新策略與抗流感藥物之研究 | zh_TW |
dc.title | New strategies for influenza detection and anti-influenzas studies | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 方俊民(Jim-Min Fang),蔡明道(Ming-Daw Tsai),鄭義循(Y.-S. Edmond Cheng),陳士隆(Steve S.-L. Chen),吳宗益(Chung-Yi Wu) | |
dc.subject.keyword | 病毒檢測,抗流感藥物,假病毒顆粒, | zh_TW |
dc.subject.keyword | virus detection,anti-influenza drug,pseudotype virus, | en |
dc.relation.page | 98 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-21 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 3.71 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。